NCT07208773 A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors
| NCT ID | NCT07208773 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | MediLink Therapeutics (Suzhou) Co., Ltd. |
| Condition | Advanced Solid Tumors |
| Study Type | INTERVENTIONAL |
| Enrollment | 260 participants |
| Start Date | 2025-10-29 |
| Primary Completion | 2027-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 260 participants in total. It began in 2025-10-29 with a primary completion date of 2027-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study was designed to evaluate the efficacy and safety of YL201 in combination with Ivonescimab (AK112) in subjects with solid tumor.
Eligibility Criteria
Inclusion Criteria: 1. Age ≥ 18 years old. 2. Inclusion criteria for the study population： Phase 1: Advanced Solid tumors. Phase 2: Extensive-stage SCLC, Non-AGA NSCLC, EGFR mutation NSCLC. 3. ECOG PS score is 0 or 1. 4. Within 7 days before the first dose, the functions of body organs and bone marrow meet the requirements. Exclusion Criteria: 1. Suitable for local curative treatment. 2. Have received previous treatment with drugs targeting B7-H3 (including antibodies, ADCs, CAR-T, and other drugs). 3. Have received previous treatment with topoisomerase I inhibitors or ADCs containing topoisomerase I inhibitors. 4. Have experienced grade ≥ 3 irAEs during previous treatment with anti-programmed death receptor (ligand) \[anti-PD-(L)1\] or other immune checkpoint inhibitors. 5. History of bleeding tendency or coagulation disorders and/or clinically significant bleeding symptoms or risks within 4 weeks before randomization. 6. Imaging studies during the screening period show that the patient has the Imaging-confirmed tumor invasion of major blood vessels. 7. Active autoimmune disease requiring systemic treatment. 8. Brain metastases or spinal cord compression. 9. Patients with uncontrolled or clinically significant cardiovascular diseases. 10. Clinically significant concurrent pulmonary diseases. 11. Known to have active pulmonary tuberculosis. Other protocol-defined inclusion/ exclusion criteria may apply
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07208773 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Advanced Solid Tumors. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07208773 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07208773 currently recruiting?
Yes, NCT07208773 is actively recruiting participants. Contact the research team at clinicaltrials@medilinkthera.com for enrollment information.
Where is the NCT07208773 trial being conducted?
This trial is being conducted at Guangzhou, China.
Who is sponsoring the NCT07208773 clinical trial?
NCT07208773 is sponsored by MediLink Therapeutics (Suzhou) Co., Ltd.. The trial plans to enroll 260 participants.